www.soligenix.com
Soligenix, Inc. is a late-stage research and development biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing biodefense vaccines and therapeutics.
What do others think of Soligenix
Presentations & Company Media
27/04/2012
Corporate presentation Apr 2012 (Presentation)27/04/2012
Fact Sheet (Presentation)
Related Research & Media
No documents available.
Company Statement:
Soligenix is a development stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against bioterrorism agents. Soligenix is developing oral beclomethasone dipropionate, a potent, topically acting corticosteroid, for the treatment and prevention of acute GVHD, prevention of acute radiation enteritis, and the treatment of pediatric Crohn’s disease.
Soligenix’s biodefense products in development are a ricin toxin vaccine called RiVax™, an anthrax vaccine called SGX204, and SGX202 for the treatment of GI ARS. Both RiVax™ and SGX204 are currently the subject of a $9.4 million NIAID grant supporting development of Soligenix’s proprietary vaccine thermostabilization technology, SGX205.
Management
Chris Schaber, CEO
Evan Myrianthopoulos, CFO
Joe Warusz, Controller (jwarusz@soligenix.com)
Sarah Millen, Admin (smillen@soligenix.com)
Contact Information
Corporate Information
Please direct Business Development inquiries to:
Joseph Warusz, CPA, MBA
Acting Chief Financial Officer
Soligenix, Inc.
29 Emmons Drive - Suite C-10
Princeton, NJ 08540
Phone: (609) 538-8200
Fax: (609) 452-6467
E-mail: jwarusz@soligenix.com
